Douglas Kelling, MD
Internal Medicine · Concord, NCNPI 1396717708
Payments from drug & device makers
Across 242 payments — averaging $347.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$32K
- Regeneron Healthcare Solutions, Inc.$16K
- Sanofi Pasteur Inc.$10K
- Sunovion Pharmaceuticals Inc.$5K
- AstraZeneca$4K
- E.r. Squibb & Sons, L.L.C.$4K
- plus $13K from 17 others
What the payments were for
- Consulting fees$8,14210%
- Speaking & faculty fees$60,43172%
- Travel & lodging$10,18112%
- Food & beverage$5,1566%
- Education$1610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 71 | $32,151 |
| Regeneron Healthcare Solutions, Inc. | 30 | $16,037 |
| Sanofi Pasteur Inc. | 16 | $9,734 |
| Sunovion Pharmaceuticals Inc. | 14 | $5,284 |
| AstraZeneca | 14 | $3,891 |
| E.r. Squibb & Sons, L.L.C. | 7 | $3,716 |
| Viiv Healthcare Company | 2 | $3,489 |
| Novo Nordisk | 9 | $2,665 |
| GSK | 21 | $2,386 |
| Sanofi | 3 | $2,111 |
| Genentech USA, Inc. | 1 | $1,455 |
| Insulet Corporation | 8 | $291 |
| Lilly USA, LLC | 13 | $275 |
| Pfizer | 15 | $189 |
| Boehringer Ingelheim | 6 | $92 |
| Boston Scientific | 2 | $74 |
| Idorsia Pharmaceuticals US Inc | 1 | $52 |
| Novartis | 3 | $48 |
| Merck | 2 | $37 |
| Sanofi-aventis U.S. LLC | 1 | $29 |
| CSL Behring | 1 | $24 |
| Bayer | 1 | $21 |
| Dynavax Technologies Corporation | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$31,085
- DUPIXENT$17,497
- FLUZONE HIGH-DOSE$9,389
- FLUBLOK QUADRIVALENT$8,532
- LONHALA MAGNAIR$4,986
- ELIQUIS$3,607
- RYBELSUS$2,520
- BREZTRI$2,500
- XOLAIR$1,455
- ANORO$1,199
- FARXIGA$1,024
- TRELEGY ELLIPTA$600
- LOKELMA$125
How this compares
$84,071 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 466 | $380,454 |
| OzempicSemaglutide | 225 | $283,992 |
| JardianceEmpagliflozin | 251 | $231,240 |
| MounjaroTirzepatide | 174 | $217,165 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 191 | $174,160 |
| TrulicityDulaglutide | 141 | $162,632 |
| GlassiaAlpha-1-Proteinase Inhibitor | 14 | $113,565 |
| XareltoRivaroxaban | 103 | $98,331 |
| VascepaIcosapent Ethyl | 177 | $79,422 |
| FarxigaDapagliflozin Propanediol | 91 | $79,149 |
| Dupixent PenDupilumab | 14 | $50,488 |
| Dupixent SyringeDupilumab | 12 | $45,876 |
| Repatha SureclickEvolocumab | 70 | $45,732 |
| NucalaMepolizumab | 12 | $45,148 |
| XifaxanRifaximin | 13 | $41,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $189 | $380,454466 claims |
| Lilly USA, LLCMounjaro, Trulicity | $275 | $379,797315 claims |
| Novo NordiskOzempic, Rybelsus | $2,665 | $301,480237 claims |
| GSKTrelegy Ellipta, Nucala, Incruse Ellipta, Breo Ellipta | $2,386 | $279,478332 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $92 | $253,702286 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $3,891 | $131,044229 claims |
| NovartisEntresto | $48 | $24,23824 claims |
| MerckJanuvia | $37 | $20,89424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Concord
- Prioty IslamConcord$1.4M
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.